Dogwood Therapeutics, Inc (NASDAQ:DWTX) Short Interest Update

Dogwood Therapeutics, Inc (NASDAQ:DWTX) was the recipient of a significant drop in short interest during the month of April. As of April 15th, there was short interest totaling 46,578 shares, a drop of 34.0% from the March 31st total of 70,605 shares. Based on an average daily trading volume, of 123,536 shares, the days-to-cover ratio is currently 0.4 days. Currently, 0.1% of the shares of the company are short sold.

Dogwood Therapeutics Stock Up 0.7%

Shares of NASDAQ DWTX traded up $0.01 during mid-day trading on Tuesday, hitting $1.35. 79,223 shares of the company were exchanged, compared to its average volume of 76,702. The stock has a 50 day simple moving average of $2.36 and a 200-day simple moving average of $3.95. Dogwood Therapeutics has a 1-year low of $1.28 and a 1-year high of $9.50. The firm has a market cap of $45.09 million, a price-to-earnings ratio of -0.07 and a beta of 2.05.

Dogwood Therapeutics (NASDAQ:DWTX) last issued its quarterly earnings results on Wednesday, March 18th. The company reported ($0.26) earnings per share for the quarter, topping the consensus estimate of ($1.22) by $0.96. Analysts anticipate that Dogwood Therapeutics will post -0.93 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have commented on DWTX. Weiss Ratings downgraded Dogwood Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Monday. HC Wainwright reiterated a “buy” rating and issued a $12.00 target price on shares of Dogwood Therapeutics in a research note on Monday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Dogwood Therapeutics has a consensus rating of “Hold” and a consensus target price of $12.00.

Hedge Funds Weigh In On Dogwood Therapeutics

A hedge fund recently bought a new stake in Dogwood Therapeutics stock. Marshall Wace LLP bought a new position in shares of Dogwood Therapeutics, Inc (NASDAQ:DWTX) during the 4th quarter, according to the company in its most recent filing with the SEC. The fund bought 11,655 shares of the company’s stock, valued at approximately $48,000. Marshall Wace LLP owned 0.51% of Dogwood Therapeutics at the end of the most recent quarter. Hedge funds and other institutional investors own 9.05% of the company’s stock.

About Dogwood Therapeutics

Dogwood Therapeutics is a clinical?stage biotechnology company dedicated to the discovery and development of novel biologic therapies aimed at reducing fibrosis and promoting tissue repair in cardiovascular and other fibrotic diseases. The company leverages a proprietary Discovery Engine that integrates high?throughput screening, functional genomics and protein engineering to identify and optimize candidate proteins and antibodies with therapeutic potential.

Dogwood’s lead programs are focused on preventing adverse cardiac remodeling following myocardial injury and improving outcomes in heart failure patients.